- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, October 15, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A letter by the editor-in-chief of The Daily Toreador referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy,” addressed an announcement by the FDA that changed wait time restrictions on gay men being allowed to donate blood from 1 year to 3 months amid the pandemic.
An article by Sports Illustrated mentioned AJMC.com’s coverage of findings presented at the American Diabetes Association’s 80th Scientific Sessions. The piece, "Racial Disparities Persist in Maternal Morbidity, Mortality and Infant Health," noted that American women die in childbirth at a higher rate than in any other developed country, with non-Hispanic Black women found to be more than 3 times more likely to have a maternal death than White women in the United States.
An opinion piece in The San Bernardino Sun cited a study published in the July 2021 issue of AJMC®, titled “Reduced Medical Spending Associated With Integrated Pharmacy Benefits.” In the study, Blue Cross and Blue Shield of Louisiana members covered by an integrated pharmacy benefit, as opposed to a pharmacy carve-out, experienced slower growth in medical spending.
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”
February 7th 2025Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Read More
